CN114364694B - 靶向usag-1分子的用于牙齿再生治疗的中和抗体 - Google Patents

靶向usag-1分子的用于牙齿再生治疗的中和抗体 Download PDF

Info

Publication number
CN114364694B
CN114364694B CN202080063186.9A CN202080063186A CN114364694B CN 114364694 B CN114364694 B CN 114364694B CN 202080063186 A CN202080063186 A CN 202080063186A CN 114364694 B CN114364694 B CN 114364694B
Authority
CN
China
Prior art keywords
seq
amino acid
antibody
usag
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080063186.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN114364694A (zh
Inventor
高桥克
菅井学
时田义人
高木淳一
三原惠美子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Fukui NUC
Kyoto University NUC
University of Osaka NUC
Original Assignee
Osaka University NUC
University of Fukui NUC
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, University of Fukui NUC, Kyoto University NUC filed Critical Osaka University NUC
Priority to CN202410516861.9A priority Critical patent/CN118307669A/zh
Publication of CN114364694A publication Critical patent/CN114364694A/zh
Application granted granted Critical
Publication of CN114364694B publication Critical patent/CN114364694B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
CN202080063186.9A 2019-07-12 2020-07-10 靶向usag-1分子的用于牙齿再生治疗的中和抗体 Active CN114364694B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410516861.9A CN118307669A (zh) 2019-07-12 2020-07-10 靶向usag-1分子的用于牙齿再生治疗的中和抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2019-130153 2019-07-12
JP2019130153 2019-07-12
JP2020080723 2020-04-30
JP2020-080723 2020-04-30
PCT/JP2020/027127 WO2021010346A1 (ja) 2019-07-12 2020-07-10 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410516861.9A Division CN118307669A (zh) 2019-07-12 2020-07-10 靶向usag-1分子的用于牙齿再生治疗的中和抗体

Publications (2)

Publication Number Publication Date
CN114364694A CN114364694A (zh) 2022-04-15
CN114364694B true CN114364694B (zh) 2024-05-10

Family

ID=74209883

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080063186.9A Active CN114364694B (zh) 2019-07-12 2020-07-10 靶向usag-1分子的用于牙齿再生治疗的中和抗体
CN202410516861.9A Pending CN118307669A (zh) 2019-07-12 2020-07-10 靶向usag-1分子的用于牙齿再生治疗的中和抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410516861.9A Pending CN118307669A (zh) 2019-07-12 2020-07-10 靶向usag-1分子的用于牙齿再生治疗的中和抗体

Country Status (6)

Country Link
US (1) US20220259298A1 (https=)
EP (1) EP4000633A4 (https=)
JP (2) JP7572668B2 (https=)
KR (1) KR20220034176A (https=)
CN (2) CN114364694B (https=)
WO (1) WO2021010346A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4115889A4 (en) * 2020-02-21 2024-10-02 Kyoto University Medicine containing usag-1-targeting rna molecule for tooth regeneration therapy
EP4474394A4 (en) * 2022-02-03 2026-04-15 Univ Kyoto Neutralizing antibody targeting a molecule called USAG-1 for treating tooth regeneration
CN116425870A (zh) * 2023-05-24 2023-07-14 陕西师范大学 一种抗新型冠状病毒n蛋白单克隆抗体31a8及其产品和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000405A1 (en) * 1997-06-30 1999-01-07 Genetics Institute, Inc. Secreted proteins
CN1618807A (zh) * 2003-11-21 2005-05-25 上海人类基因组研究中心 分泌蛋白及其编码序列和用途
CN101821291A (zh) * 2007-10-12 2010-09-01 诺瓦提斯公司 抗硬骨素抗体的组合物和应用方法
CN101925611A (zh) * 2007-11-21 2010-12-22 安姆根有限公司 Wise结合剂和表位
CN105820249A (zh) * 2004-07-09 2016-08-03 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3 抗体
CN109071648A (zh) * 2015-10-23 2018-12-21 辉瑞有限公司 抗il-2抗体及其组合物和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023356A1 (en) * 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
WO2009131553A2 (en) 2006-12-29 2009-10-29 Osteogenex Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
GB0911060D0 (en) 2009-06-26 2009-08-12 Ge Healthcare Uk Ltd Methods for predicting the toxicity of a chemical
WO2011075636A2 (en) * 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
KR102155531B1 (ko) * 2012-03-30 2020-09-15 도레이 카부시키가이샤 간암의 치료 및/또는 예방용 의약 조성물
WO2015120138A2 (en) * 2014-02-05 2015-08-13 Dana-Farber Cancer Institute, Inc. AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
KR20190044070A (ko) * 2016-08-03 2019-04-29 넥스트큐어 인코포레이티드 Lair 신호 변환을 조정하기 위한 조성물 및 방법

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000405A1 (en) * 1997-06-30 1999-01-07 Genetics Institute, Inc. Secreted proteins
CN1618807A (zh) * 2003-11-21 2005-05-25 上海人类基因组研究中心 分泌蛋白及其编码序列和用途
CN105820249A (zh) * 2004-07-09 2016-08-03 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3 抗体
CN101821291A (zh) * 2007-10-12 2010-09-01 诺瓦提斯公司 抗硬骨素抗体的组合物和应用方法
CN101925611A (zh) * 2007-11-21 2010-12-22 安姆根有限公司 Wise结合剂和表位
CN109071648A (zh) * 2015-10-23 2018-12-21 辉瑞有限公司 抗il-2抗体及其组合物和用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Anti–USAG-1 therapy for tooth regeneration through enhanced BMP signaling;A. Murashima-Suginami et al.;《Sci. Adv.》;第7卷;1-10 *
Gremlin在马兜铃酸诱导肾小管上皮细胞转分化中的作用研究;李艺;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》(第1期);E067-27 *
Interactions between Shh, Sostdc1 and Wnt signaling and a new feedback loop for spatial patterning of the teeth;Sung-Won Cho et al.;《Development》;第138卷(第9期);摘要，第1807页右栏第1段，第1810页左栏最后一段 *
Sostdc1, a secreted dual BMP and WNTantagonist, is differentially expressed inRCS rdy and rdy rat retinal pigmentepithelial cells;Marc Mordekhai Abitbol et al.;《ARVO Annual Meeting Abstract》;第58卷(第610期);1-2 *

Also Published As

Publication number Publication date
JP7572668B2 (ja) 2024-10-24
CN114364694A (zh) 2022-04-15
EP4000633A4 (en) 2024-02-21
EP4000633A1 (en) 2022-05-25
JP2025004094A (ja) 2025-01-14
WO2021010346A1 (ja) 2021-01-21
US20220259298A1 (en) 2022-08-18
CN118307669A (zh) 2024-07-09
KR20220034176A (ko) 2022-03-17
JP2021176829A (ja) 2021-11-11

Similar Documents

Publication Publication Date Title
US20260091108A1 (en) Anti-ccr8 antibodies and uses thereof
JP7044399B2 (ja) タウ免疫療法
JP6794348B2 (ja) ヒト化抗ｏｘ４０抗体及びその使用
KR102506091B1 (ko) 타우 면역요법
BR112020017296A2 (pt) Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm
US20170073406A1 (en) Compositions and methods for growth factor modulation
US20180208648A1 (en) Gdf11 binding proteins and uses thereof
BR112017018941B1 (pt) Molécula de ligação a cd20, seu uso, composição e método in vitro para direcionar a morte mediada por complemento de uma célula que expressa cd20
JP2020524000A (ja) 抗ｂｃｍａ重鎖のみ抗体
JP2025004094A (ja) 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体
US20220396632A1 (en) Anti-psgl-1 compositions and methods for modulating myeloid cell infalmmatory phenotypes and uses thereof
CN110494449B (zh) Alt-803与抗cd38抗体组合用于癌症治疗
US10556947B2 (en) Binding molecule that binds specifically to the precursor of brain-derived neurotrophic factor
CN109475625A (zh) 用于治疗脊髓性肌肉萎缩症的组合物和方法
JP2015509960A (ja) Ｂ細胞媒介炎症性疾患を治療するための方法
CN113412130A (zh) 用于诊断和治疗癌症及其他疾病的对促肿瘤癌症相关成纤维细胞的识别和靶向
AU2014305658A1 (en) An antibody therapy for amyloid beta disease
FR3075200A1 (fr) Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc
KR20230026489A (ko) 소르틸린을 인지하는 항체
JP6872756B2 (ja) 抗Ｍｙｌ９抗体
US20250136674A1 (en) Usag-1 molecule-targeting neutralizing antibody for tooth regeneration treatment
HK40073445A (en) Neutralizing antibody for tooth regeneration treatment targeting usag-1 molecule
HK40107636A (zh) 靶向usag-1分子的用於牙齿再生治疗的中和抗体
HK40073445B (zh) 靶向usag-1分子的用於牙齿再生治疗的中和抗体
HK40114319A (zh) 靶向usag-1分子的用於牙齿再生治疗的中和抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40073445

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant